1
Clinical Trials associated with nL-PRPH2-001 / Active, not recruitingPhase 1/2IIT An Open-label Single Center Study of an Individualized Antisense Oligonucleotide Treatment for Retinal Dystrophy Associated With a Pathogenic PRPH2 Variant
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
100 Clinical Results associated with nL-PRPH2-001
100 Translational Medicine associated with nL-PRPH2-001
100 Patents (Medical) associated with nL-PRPH2-001
100 Deals associated with nL-PRPH2-001